Crossbow Therapeutics is a Cambridge, Massachusetts biotechnology company building a new class of cancer immunotherapies. Its T-Bolt platform engineers TCR-mimetic antibodies - T-cell engagers that recognize tiny peptide fragments displayed on a cancer cell's surface (peptide-HLA complexes), opening up intracellular proteins that conventional antibodies cannot reach. The lead program, CBX-250, is a first-in-class T-cell engager in a Phase 1 trial for relapsed or refractory myeloid malignancies. Backed by more than $157M in venture funding, Crossbow aims to expand the universe of targetable cancer antigens.
Helix is a San Mateo-based population genomics company that helps health systems, life sciences companies, and public health organizations weave genomic data into everyday patient care. Built around its proprietary Exome+ assay and the first FDA-authorized whole exome sequencing platform, Helix powers large-scale precision health programs at partners like Mayo Clinic and Renown Health, with a research network spanning hundreds of thousands of sequenced participants.
Mirador Therapeutics is a San Diego precision-medicine company building first- and best-in-class therapies for immune-mediated inflammatory and fibrotic diseases. Its Mirador360 engine fuses human genetics, multi-modal patient data, AI and advanced analytics to find novel targets, design combination therapies and identify the patients most likely to respond. Founded in 2024 by the former Prometheus Biosciences leadership team, Mirador launched with more than $400 million and has since raised over $650 million total.
Paradigm4 builds scientific data management and analytics software for the life sciences. Its flagship REVEAL platform and SciDB array database let pharma, biotech, and research institutions integrate and analyze massive multimodal datasets - genomics, multi-omics, imaging, clinical records, wearables, and environmental data - to find biomarkers and validate drug targets. Co-founded in 2010 by entrepreneur Marilyn Matz and Turing Award-winning MIT professor Michael Stonebraker, the company is based in Waltham, Massachusetts.
Strand Therapeutics is a clinical-stage biotech building 'programmable' mRNA medicines - drugs engineered with logic circuits so they switch on the right protein, in the right cell, at the right time. Spun out of MIT in 2017 by synthetic biologists who wrote the first programming language for mRNA, Strand's lead candidate STX-001 is a self-replicating mRNA that makes tumors manufacture their own IL-12, turning cold cancers hot from the inside. Backed by Kinnevik, Regeneron, Amgen and Eli Lilly with over $250M raised.
Totus Medicines is a clinical-stage precision medicines company in Emeryville, California, building covalent small-molecule drugs against historically undruggable targets. Its AI-powered OmniDEL platform screens billions of DNA-encoded covalent candidates against thousands of targets inside living cells, surfacing molecules that older methods miss. Its lead program, TOS-358, is the first and only covalent PI3Ka inhibitor in clinical development, showing class-leading tolerability and strong disease control in breast, endometrial, and head & neck cancers.
Beacon Biosignals is a Boston-based neurotechnology company that pairs FDA-cleared wearable EEG hardware with AI to turn brain electrical activity - especially during sleep - into scalable, at-home neurodiagnostics. Its platform powers drug development, clinical trials, and precision medicine across neurology, psychiatry, and sleep medicine.
Abhishek Jha is the Co-Founder and CEO of Elucidata, a San Francisco-based AI company making biomedical data AI-ready for drug discovery and pharmaceutical R&D. A trained physical chemist with a PhD from the University of Chicago and postdoctoral work at MIT, he spent years at Agios Pharmaceuticals contributing to four FDA-approved first-in-class therapies before co-founding Elucidata in 2015. Under his leadership, the company has raised over $22.7M in funding, grown to 170 employees, and achieved $22.2M ARR, while evolving from a data-curation platform into an AI company solving out-of-distribution (OOD) problems in biomedical research - work that earned Elucidata recognition as one of Fast Company's Most Innovative Companies in 2024.
Jahangir Mohammed is a serial entrepreneur and inventor who built Jasper Technologies into the world's largest IoT platform - sold to Cisco for $1.4 billion in 2016 - then turned his attention to metabolic disease. As Founder and CEO of Twin Health, he is using AI-powered whole-body digital twin technology to reverse chronic conditions like Type 2 diabetes, with clinical results published in the New England Journal of Medicine Catalyst showing 71% of participants achieving A1C below 6.5% while eliminating most medications. Twin Health has raised $335 million total and reached a $950 million valuation in 2025.
Abdera Therapeutics is a precision oncology biotech engineering antibody-based radiopharmaceuticals that deliver therapeutic radioisotopes directly to tumor cells while sparing healthy tissue. Built around its proprietary ROVEr platform, the company is advancing ABD-147 in Phase 1 trials for small cell lung cancer and large cell neuroendocrine carcinoma, with a second program, ABD-320, on deck.
Frontier Medicines is a precision-medicine biotech using chemoproteomics, covalent chemistry, and machine learning to drug proteins long considered 'undruggable.' Its lead candidate, FMC-376, is a first-in-class dual ON/OFF inhibitor of KRAS G12C now in the Phase 1/2 PROSPER trial. Backed by $315M+ in venture funding and a major AbbVie partnership, the company is one of the most-watched names in next-generation targeted cancer therapy.
Kardigan is a South San Francisco heart health company modernizing cardiovascular drug development. Founded by the team behind MyoKardia, it pairs a late-stage clinical pipeline in dilated cardiomyopathy, acute severe hypertension and calcific aortic valve stenosis with a 'cardiac intelligence' platform - real-world patient data and AI - to match disease drivers to the right responders.
Dr. Gauri Naik is a Ph.D. biotechnologist, serial entrepreneur, and Co-Founder & CEO of OptraHEALTH, a Silicon Valley AI health-tech company building conversational AI and revenue cycle automation tools for genetics, genomics, and clinical workflows. With 11 U.S. patents, a career spanning digital pathology (BioImagene, acquired by Roche), and products deployed at leading health systems across the US, Europe, and Asia, she sits at the intersection of molecular biology, machine learning, and enterprise health IT.
Yongwei Zhang is the CEO of Complete Genomics and MGI Americas, leading one of the most ambitious efforts to make whole-genome sequencing fast, accurate, and affordable at scale. With a PhD in Mechanical Engineering from Johns Hopkins and dual bachelor's degrees from Tsinghua University, Zhang brings a rare blend of optics precision, software fluency, and entrepreneurial grit to the genomics frontier. He architected the DNBSEQ sequencing platform series now used by over 2,600 researchers in 100 countries, and has positioned Complete Genomics as a formidable challenger to Illumina's market dominance - at a fraction of the cost.
Elaine Cheung is Chief Business Officer at Moonwalk Biosciences, a South San Francisco biotech backed by $57 million in funding and co-founded by CRISPR pioneer Feng Zhang and former Illumina CTO Alex Aravanis. With 20+ years navigating the inflection points of genomic medicine - from spinning GRAIL out of Illumina, helping architect its $900M+ Series B, and steering Lyell Immunopharma through its IPO - Cheung brings a rare combination of scientific literacy and deal-making precision. At Moonwalk, she is helping build the business infrastructure for a company that has pivoted from epigenetic editing to siRNA-based therapeutics targeting adipose biology and obesity.
Eric Green is the Founder and CEO of Trace Neuroscience, a South San Francisco biotech company racing to develop the first effective ASO therapy for ALS. A Harvard-and-Stanford-trained physician-scientist with a background in cardiology, Green co-founded iLab Solutions (acquired by Agilent), Respira Design (Stanford $50K Challenge winner), and Maze Therapeutics before launching Trace with a $101 million Series A in November 2024. Trace's lead program targets UNC13A - a protein lost in ALS patients - using an antisense oligonucleotide designed to restore healthy nerve-muscle communication. With clinical trials targeting early 2026, Green is betting human genetics can do for ALS what it did for heart failure.
Maneesh Jain is the CEO and Co-founder of Mirvie, a South San Francisco-based biotech company pioneering RNA-based blood tests to predict pregnancy complications like preeclampsia and preterm birth months before symptoms occur. A serial entrepreneur with 20+ years in life sciences and more than $1.5B in combined exits across five prior startups - including Ion Torrent (acquired by Life Technologies) and Cirina (acquired by GRAIL) - Jain trained at the Stanford Genome Technology Center and holds a BS from Caltech and a Master's in Applied Physics from Stanford. Mirvie has raised over $90 million from investors including Khosla Ventures, GV, General Catalyst, and the Gates Foundation, and received FDA Breakthrough Device Designation for its preeclampsia risk test in 2022.
Ron Alfa is Co-Founder and CEO of Noetik, an AI-native biotech building foundation models trained on one of the world's largest collections of multimodal human tumor data. A physician-scientist with an MD-PhD from Stanford and an MA in the History of Medicine from UCL, Alfa spent six years at Recursion Pharmaceuticals rising to SVP Head of Research before co-founding Noetik in 2023. The company's OCTO-VC virtual cell models and TARIO-2 autoregressive transformer are designed to predict which cancer patients will respond to which therapies - attacking the 95% failure rate of cancer clinical trials from the data side rather than the pharmacology side. In January 2026, Noetik signed a landmark $50M licensing deal with GSK, one of the first large-scale transactions to monetize a biological foundation model as a scalable enterprise asset.
Stig K. Hansen is a Danish-American biochemist and serial biotech founder who co-founded Kimia Therapeutics in 2023, a Berkeley-based precision chemistry company applying machine learning and automated synthesis to drug discovery. He previously co-founded and led Carmot Therapeutics for 15 years, inventing Chemotype Evolution technology that contributed to LUMAKRAS - the world's first FDA-approved KRAS G12C inhibitor for non-small cell lung cancer. Carmot was acquired by Roche for up to $3.1 billion in January 2024. At Kimia, Hansen is pioneering the ATLAS platform (AcTive Learning with Automated Synthesis and Screening), which integrates high-throughput chemistry, genome editing, and AI to map druggable chemical space at unprecedented scale. The company raised a $55 million Series A in December 2023 led by The Column Group and Dimension.
Tom Willis, PhD, is a genomics entrepreneur with more than 20 years of company-building experience who became CEO of Arima Genomics in June 2025. A Yale and Stanford physicist turned biotech serial founder, he co-invented Molecular Inversion Probe technology, built two genomics companies from the ground up - ParAllele BioScience (acquired by Affymetrix) and Sequenta (whose ClonoSEQ assay became NCCN-standard for leukemia and lymphoma residual disease testing) - then spent a decade as Venture Partner at Illumina Ventures before stepping in to lead Arima, a company pioneering 3D genomics for cancer diagnostics.
Chris Varma, Ph.D., is Co-Founder, Chairman, and CEO of Frontier Medicines, a clinical-stage biotech attacking cancer's 'undruggable' proteins using chemoproteomics, covalent chemistry, and machine learning. A serial biotech founder with 20+ years in life sciences, he previously co-founded Blueprint Medicines (acquired by Sanofi for $9B+ in 2025) and Warp Drive Bio (acquired by Revolution Medicines in 2018), and held investor roles at Third Rock Ventures, Flagship Pioneering, and MPM Capital. His career spans the FDA, Novartis, and three successful company builds - with Frontier Medicines now advancing FMC-376, a first-in-class dual KRAS G12C inhibitor, through Phase 1/2 clinical trials.
Kunwoo Lee is the CEO and Co-founder of BreezeBio (formerly GenEdit), a Brisbane, California-based biotech company pioneering non-viral gene delivery through its proprietary NanoGalaxy platform. A Siebel Scholar and Forbes 30 Under 30 honoree who earned his PhD from UC Berkeley-UCSF Joint Program in Bioengineering, Lee co-founded GenEdit in 2016 alongside Professor Niren Murthy and fellow researcher Hyo Min Park, building out a polymer nanoparticle library of thousands of chemically distinct compounds capable of delivering diverse genetic payloads to specific tissues. The company has raised over $118 million including a $60M Series B in February 2026, struck a landmark $644M collaboration deal with Genentech, and rebranded to BreezeBio to signal its pivot from platform company to clinical-stage therapeutics developer advancing BRZ-101 for Type 1 Diabetes.
Tassos Gianakakos is a Greek-American biotech entrepreneur and the co-founder, CEO, and Chair of Kardigan, a cardiovascular drug discovery company he built from the ashes of MyoKardia — the precision-medicine heart company he led to a $13.1 billion acquisition by Bristol Myers Squibb in 2020. At Kardigan, he is applying the same playbook: marrying real-world clinical data, AI tools, and deep cardiovascular biology to deliver personalized medicines for heart disease — a field he believes is where oncology was 20 years ago. With $554 million raised and three late-stage clinical programs underway, Gianakakos is on a mission to make cardiovascular disease preventable and curable.
Andre Esteva, PhD, is the co-founder and CEO of ArteraAI, a medical AI company whose test for personalizing prostate cancer therapy is included in NCCN clinical guidelines, reimbursed by Medicare, and deployed internationally. A Stanford-trained AI scientist whose Nature cover paper first demonstrated that AI could match dermatologists at diagnosing skin cancer, Esteva has co-founded four companies with a combined market cap of $2.2B. Named to TIME100 Health 2025 and Modern Healthcare's 40 Under 40 for 2025, he leads a company that raised $175M total and was named a TIME 2024 Best Invention.
Mark Lee, MD, PhD is the CEO and Co-Founder of N-Power Medicine, a Redwood City-based company reinventing how oncology clinical trials reach patients. A medical oncologist and scientist trained at Stanford and Harvard, Lee has spent his career at the frontier of personalized medicine - from developing Oncotype DX diagnostics at Genomic Health, to helping build early cancer detection at GRAIL, to leading personalized healthcare at Genentech/Roche. In 2021, he co-founded N-Power Medicine to embed research infrastructure directly into community oncology clinics, combining AI, embedded staff, and real-time registries to dramatically expand clinical trial access. After raising a $72M Series B led by Merck's Global Health Innovation Fund, N-Power acquired Syapse in late 2024 to build the largest community-based prospective clinical research network in oncology.
Kevin Parker, Ph.D. is the co-founder and CEO of Cartography Biosciences, a South San Francisco-based oncology company using single-cell genomics and AI to map the tumor antigen landscape and build precision immunotherapies. A Harvard and Stanford alumnus who founded the company straight out of his PhD, Parker has raised $124M in total funding, struck a landmark collaboration with Gilead Sciences, received FDA IND approval for his lead drug CBI-1214, and dosed the first patient in a Phase 1 colorectal cancer trial in early 2026 - all before most scientists finish a second postdoc.
Othman Laraki is the co-founder and CEO of Color Health, a company he has steered from affordable genetic testing to pandemic-scale COVID infrastructure to a $4.6B-valued virtual cancer clinic serving over 7 million Americans. A Moroccan-born Stanford and MIT alumnus who learned to code by typing programs from magazines in Casablanca, he built Twitter's first revenue products as VP of Product before pivoting to healthcare. Today he sits on the American Cancer Society board as its only non-clinician, partners with Google and OpenAI to deploy AI in oncology, and angel invests in companies like Pinterest, Slack, and Instacart.